Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Pfizer Inc filings on SEC EDGAR ↗
For the three months ended September 27, 2026, Pfizer reported total revenues of $16.58 billion, a slight decrease from $16.65 billion in the prior year period. Net income attributable to common shareholders for the quarter was $3.24 billion ($0.56 per diluted share), down from $3.54 billion ($0.62 per diluted share) in the same period of 2025.
Pfizer reported Q3 2026 revenues of $16.6 billion, with 32% operational growth from launched and acquired products. The company raised its full-year 2026 revenue guidance to $62.0-$64.0 billion and appointed Cecile Guegan as its new Chief Financial Officer.
Term
Q3 2026
“Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value. Our obesity program continued to advance and recent milestones in oncology, immunology and vaccines further demonstrate the potential of our pipeline. With a robust slate of expected catalysts ahead, I believe we're well positioned to deliver meaningful new medicines for patients and lasting value in the years ahead.”
Dr. Albert Bourla, Chairman and CEO of Pfizer
“Our third-quarter results reflect strong commercial performance globally and continued operational discipline. This quarter, our non-COVID products delivered strong 7% operational revenue growth, and I’m particularly pleased with the 32% year-over-year operational revenue growth from our launched and acquired products. Today, we are raising our full-year 2026 Revenue and Adjusted diluted EPS guidance, reflecting our strong year-to-date performance and confidence in our business.”